End points to establish the efficacy of new agents in the treatment of acute leukemia Academic Article uri icon


MeSH Major

  • Hematologic Agents
  • Leukemia
  • Randomized Controlled Trials as Topic


  • Federal regulations provide 2 pathways for approval of new agents for the treatment of acute leukemia, regular and accelerated approval. Regular approval requires evidence of clinical benefit, which is generally defined as either prolongation of life or improved quality of life, or an effect on an end point established as a surrogate for clinical benefit. Accelerated approval can be obtained based on demonstration of an effect on a surrogate measure "reasonably likely" to predict clinical benefit, but requires demonstration of clinical benefit after approval as well. The acute leukemias are a heterogeneous and relatively uncommon group of diseases. The design and execution of prospective randomized clinical trials demonstrating prolongation of life or improved quality of life for patients with these disorders can be difficult and costly and require lengthy follow-up. Thus, the development of novel trial design and inclusion of validated surrogate markers for clinical benefit are needed. To explore some of the issues pertinent to the choice of end points for drug approval in acute leukemia, the Food and Drug Administration invited the American Society of Hematology to participate in the organization and conduct of a joint workshop. In this report, we present the results of that effort.

publication date

  • March 2007



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1182/blood-2006-08-041152

PubMed ID

  • 17095617

Additional Document Info

start page

  • 1810

end page

  • 6


  • 109


  • 5